CD8⁺ T Cells in Cancer

 Monday, May 9, 2022     3:45 PM – 5:45 PM ET     Oregon Ballroom 201

CD8⁺ T Cells in Cancer

Chairs

• Andrea Schietinger, Memorial Sloan Kettering Cancer Ctr.
• David Masopust, Univ. of Minnesota

Speakers

• Michael William Rudloff, Vanderbilt Univ. Med. Ctr., Hallmark features of T cell dysfunction are established within hours after tumor antigen encounter
• Nataliya Prokhnevska, Emory Univ., CD8 T cell activation in cancer is comprised of two distinct phases
• Hazem E. Ghoneim, Ohio State Univ. Col. of Med., Rebalancing TGFβ1/BMP Signaling Epigenetically Reprograms Fully Exhausted Human CD8 T Cells into a Functional State
• Benjamin M. Murter, Univ. of Pittsburgh Sch. of Med., PIK3IP1/TrIP Immune Regulation on CD8⁺ T Cells Restricts Anti-Tumor Immunity
• Rachel Cantrell, Univ. of Cincinnati Col. of Med., The role of the Thrombin/PAR axis in modulating CD8+ T cell anti-tumor immunity
• Haitao Wen, Ohio State Univ., Sushi domain containing 2 suppresses CD8⁺ T cell antitumor immunity by targeting IL-2 receptor signaling
• Emily C. Lerner, Duke Univ. Sch. of Med., CD8 T cells licensed with immune checkpoint blockade kill murine tumors lacking MHC-I
• Pamela Rosato, Geisel Sch. of Med., Dartmouth Col., Functional virus-specific memory CD8+ T cells survey glioblastoma